Patents by Inventor Michel Demeule

Michel Demeule has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12269902
    Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer.
    Type: Grant
    Filed: August 30, 2023
    Date of Patent: April 8, 2025
    Assignee: Transfert Plus, S.E.C.
    Inventors: Richard Béliveau, Borhane Annabi, Michel Demeule, Alain Larocque, Jean-Christophe Currie, Cyndia Charfi
  • Publication number: 20240156971
    Abstract: The present application relates to methods and uses of conjugates comprising antitumor agents (e.g., chemotherapeutic agents) conjugated to peptide compounds targeting Sortilin-expressing cancer stem cells (CSCs), in embodiments for the treatment of poor prognosis cancers refractory to standard antitumor therapies associated the presence of Sortilin-expressing CSCs, and for preventing or treating cancer relapse or recurrence.
    Type: Application
    Filed: February 24, 2022
    Publication date: May 16, 2024
    Applicants: TRANSFERT PLUS, SOCIÉTÉ EN COMMANDITE, THERATECHNOLOGIES INC.
    Inventors: Richard Beliveau, Michel Demeule, Borhane Annabi, Cyndia Charfi, Alain Larocque, Jean-Christophe Currie, Alain Zgheib, Christian Marsolais
  • Patent number: 11780882
    Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: October 10, 2023
    Assignee: Transfert Plus, S.E.C.
    Inventors: Richard Béliveau, Borhane Annabi, Michel Demeule, Alain Larocque, Jean-Christophe Currie, Cyndia Charfi
  • Patent number: 11034727
    Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer and increasing cellular internalization of said peptide compounds. The peptide compounds are selected from the following group consisting of; GVRAKAGVRNMFKSESY as set forth in SEQ ID NO: 9; GVRAKAGVRN(Nle)FKSESY as set forth in SEQ ID NO: 10; and YKSLRRKAPRWDAPLRDPALRQLL as set forth in SEQ ID NO: 11; and wherein at least one protecting group and/or at least one labelling agent is connected to said peptide compound.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: June 15, 2021
    Assignee: TRANSFERT PLUS, S.E.C.
    Inventors: Richard Béliveau, Borhane Annabi, Michel Demeule, Alain Larocque, Jean-Christophe Currie, Cyndia Charfi
  • Patent number: 9914754
    Abstract: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic selected from the group consisting of neurotensin, a neurotensin analog, or a neurotensin receptor agonist. The compounds of the invention can be used to treat any disease in which increased neurotensin activity is useful and can be used to induce hypothermia or analgesia.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: March 13, 2018
    Assignee: Angiochem Inc.
    Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Carine Thiot, Catherine Gagnon
  • Publication number: 20180015180
    Abstract: The present invention relates to short polypeptides (e.g., fewer than 19 amino acids in length) and longer polypeptides (e.g., 19 or more amino acids in length) having one or more D-amino acids as targeting moieties. These polypeptides, when conjugated to agents (e.g., therapeutic agents or transport vectors) are capable of transporting the agents across the BBB or into particular cell types. In particular, the short polypeptides can include one or more D-amino acids. These compounds are therefore particularly useful in the treatment of neurological diseases or diseases associated with particular cell types, organs, or tissues.
    Type: Application
    Filed: February 22, 2017
    Publication date: January 18, 2018
    Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Carine Thiot-sabot, Laurence Peslherbe
  • Publication number: 20170326233
    Abstract: The present invention relates to antibody-polypeptide-cytotoxin conjugates and methods of making, packaging, and using the conjugates. The polypeptide can be a Kunitz-type protease inhibitor or a derivative thereof that facilitates transport of the conjugate across the blood-brain barrier and/or into cancer cells outside the CNS, and the antibody moiety selectively binds a target within the CNS or in peripheral tumors to direct the cytotoxic agent to that target (e.g., a tumor or cancer cell). The conjugates can be further defined by the inclusion of a linker between the antibody moiety and the polypeptide; by the number of polypeptides and cytotoxic agents conjugated thereto; by the positions at which the entities within the conjugates are bound to one another; and by the larger configuration of the conjugate. Modified polypeptides (e.g., polypeptides conjugated to cytotoxic agents but not to an anti-body moiety), pharmaceutical compositions, kits (e.g.
    Type: Application
    Filed: November 13, 2015
    Publication date: November 16, 2017
    Inventors: Michel Demeule, Christian Che, Sanjoy Das, Gaoqiang Yang
  • Publication number: 20170281787
    Abstract: The present invention relates to antibody-polypeptide-cytotoxin conjugates and methods of making, packaging, and using the conjugates. The polypeptide can be a Kunitz-type protease inhibitor or a derivative thereof that facilitates transport of the conjugate across the blood-brain barrier and/or into cancer cells outside the CNS, and the antibody moiety selectively binds a target within the CNS or in peripheral tumors to direct the cytotoxic agent to that target (e.g., a tumor or cancer cell). The conjugates can be further defined by the inclusion of a linker between the antibody moiety and the polypeptide; by the number of polypeptides and cytotoxic agents conjugated thereto; by the positions at which the entities within the conjugates are bound to one another; and by the larger configuration of the conjugate. Modified polypeptides (e.g., polypeptides conjugated to cytotoxic agents but not to an antibody moiety), pharmaceutical compositions, kits (e.g.
    Type: Application
    Filed: November 11, 2016
    Publication date: October 5, 2017
    Inventors: Jean-Paul Castaigne, Gaoqiang Yang, Christian Che, Michel Demeule
  • Patent number: 9713646
    Abstract: The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: July 25, 2017
    Assignee: Angiochem Inc.
    Inventors: Richard Béliveau, Michel Demeule, Christian Che, Anthony Regina
  • Patent number: 9687561
    Abstract: The invention relates to dendrimers conjugated to multiple targeting peptides and one or more therapeutic, diagnostic, or imaging agents for delivery of such agents across the blood-brain barrier and into certain cell types including, cells expressing the LRP-1 receptor. Also described are methods of making compounds that comprise dendrimers conjugated to targeting peptides and therapeutic, diagnostic, or imaging agents.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: June 27, 2017
    Assignee: Angiochem Inc.
    Inventors: Michel Demeule, Alain Larocque, Gaoqiang Yang, Sasmita Tripathy
  • Publication number: 20170080100
    Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptide derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides. The present invention also relates to the use of these polypeptide for transporting an antibody or antibody fragment across the blood-brain barrier of an individual and in the treatment and diagnosis of neurological diseases.
    Type: Application
    Filed: January 21, 2016
    Publication date: March 23, 2017
    Inventors: Richard Beliveau, Michel Demeule, Christian Che, Anthony Regina
  • Publication number: 20160263236
    Abstract: The present invention relates to short polypeptides (e.g., fewer than 19 amino acids in length) and longer polypeptides (e.g., 19 or more amino acids in length) having one or more D-amino acids as targeting moieties. These polypeptides, when conjugated to agents (e.g., therapeutic agents or transport vectors) are capable of transporting the agents across the BBB or into particular cell types. In particular, the short polypeptides can include one or more D-amino acids. These compounds are therefore particularly useful in the treatment of neurological diseases or diseases associated with particular cell types, organs, or tissues.
    Type: Application
    Filed: October 23, 2015
    Publication date: September 15, 2016
    Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Carine Thiot-Sabot, Laurence Peslherbe
  • Publication number: 20160213760
    Abstract: The present invention relates to protein conjugates comprising an aprotinin-derived polypeptide, which facilitates transport of the conjugate across the blood-brain barrier, and an antibody moiety that selectively binds a target within the CNS. The protein conjugates are further defined by the inclusion of a linker; by the number of polypeptides conjugated to each antibody moiety; by the positions at which the antibody moiety and the polypeptides are conjugated; and by the larger configuration of the conjugate (in which every polypeptide is linked only to the antibody moiety). Modified aprotinin-derived polypeptides, linker-bound antibody moieties, pharmaceutical compositions, kits, and methods of making and using the protein conjugates are also features of the invention.
    Type: Application
    Filed: November 12, 2013
    Publication date: July 28, 2016
    Inventors: Sasmita Tripathy, Michel Demeule, Jean-Christophe Currie
  • Patent number: 9365634
    Abstract: Based on our identification of a polypeptide (Angiopep-7) that is efficiently transported to cells such as liver, lung, kidney, spleen, and muscle, the invention provides polypeptides, conjugates including the polypeptides, and methods for treating diseases associated with these cell types. Unlike other aprotinin related polypeptides identified herein (including Angiopep-3, Angiopep-4a Angiopep-4b Angiopep-5, and Angiopep-6) which efficiently cross the blood-brain barrier (BBB), Angiopep-7 is not efficiently transported across the BBB.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: June 14, 2016
    Assignee: Angiochem Inc.
    Inventors: Richard Béliveau, Michel Demeule, Christian Che, Anthony Regina
  • Publication number: 20160106856
    Abstract: The present invention relates to antibody-polypeptide-cytotoxin conjugates and methods of making, packaging, and using the conjugates. The polypeptide can be a Kunitz-type protease inhibitor or a derivative thereof that facilitates transport of the conjugate across the blood-brain barrier and/or into cancer cells outside the CNS, and the antibody moiety selectively binds a target within the CNS or in peripheral tumors to direct the cytotoxic agent to that target (e.g., a tumor or cancer cell). The conjugates can be further defined by the inclusion of a linker between the antibody moiety and the polypeptide; by the number of polypeptides and cytotoxic agents conjugated thereto; by the positions at which the entities within the conjugates are bound to one another; and by the larger configuration of the conjugate. Modified polypeptides (e.g., polypeptides conjugated to cytotoxic agents but not to an antibody moiety), pharmaceutical compositions, kits (e.g.
    Type: Application
    Filed: August 14, 2013
    Publication date: April 21, 2016
    Inventors: Jean-Paul Castaigne, Gaoqiang Yang, Christian Che, Michel Demeule
  • Patent number: 9221867
    Abstract: The present invention relates to improvements in the field of drug delivery. More particularly, the invention relates to a non-invasive and flexible method and carrier for transporting a compound or drug across the blood-brain barrier of an individual. In particular the present invention relates to a carrier for transporting an agent attached thereto across a blood-brain barrier, wherein the carrier is able to cross the blood-brain barrier after attachment to the agent and thereby transport the agent across the blood-brain barrier. The present invention relates to improvements in the field of drug delivery. More particularly, the invention relates to a non-invasive and flexible method and carrier for transporting a compound or drug across the blood-brain barrier of an individual.
    Type: Grant
    Filed: January 5, 2004
    Date of Patent: December 29, 2015
    Assignee: Angiochem Inc.
    Inventors: Richard Béliveau, Michel Demeule
  • Publication number: 20150314010
    Abstract: The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer.
    Type: Application
    Filed: March 2, 2015
    Publication date: November 5, 2015
    Inventors: Richard Béliveau, Michel Demeule, Christian Che, Anthony Regina
  • Patent number: 9173891
    Abstract: Ovarian cancer is treated with conjugates of an anticancer agent and an Angiopep-2 polypeptide analog (i.e. a polypeptide comprising an amino acid sequence at least 80% identical to Seq. ID NO:97). Such treatment includes utility in treating metastatic ovarian cancer and in treating patients who have previously exhibited resistance to standard chemotherapeutic agents. Preferred anticancer agents include taxanes while the preferred conjugate is ANG1005, a conjugate comprising three molecules of paclitaxel conjugated to the peptide Angiopep-2.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: November 3, 2015
    Assignee: Angiochem, Inc.
    Inventors: Jean-Paul Castaigne, Michel Demeule, Betty Lawrence
  • Patent number: 9161988
    Abstract: The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: October 20, 2015
    Assignee: Angiochem Inc.
    Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Carine Thiot, Catherine Gagnon, Betty Lawrence
  • Publication number: 20150290341
    Abstract: The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, a compound that includes iduronate-2-sulfatase conjugated to Angiopep-2 through a linker formed by specific click chemistry reactions. In certain embodiments, these compounds, owing to the presence of the targeting moiety, can cross the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features pharmaceutical compositions containing such compounds and methods for treating lysosomal storage disorders (e.g., mucopolysaccharidosis Type II) using such compounds.
    Type: Application
    Filed: December 2, 2013
    Publication date: October 15, 2015
    Applicant: Anglachem Inc.
    Inventors: Dominique Boivin, Jean-Paul Castaigne, Michel Demeule, Sasmita Tripathy, Jean-Christophe Currie, Simon Lord-Dufour